Inclusion Criteria:  Patients with a confirmed positive Polymerase chain reaction(PCR) test for SARS COV-2 Adults of ≥ 18 years Evidence of a personally signed and dated informed consent document indicating that the participant(or their legal representative) has been informed of all pertinent aspects of the study  Exclusion Criteria:  Patients with contraindication to the use of hydroxychloroquine e.g. known allergy to hydroxychloroquine Patients enrolled in another interventional study which may interfere with study results Patients on medication that are known to have clinically significant interactions with the study drug e.g. digoxin, piperaquine, lumefantrine. Patients presenting with severe/critically ill COVID-19 (World Health Organization Ordinal scale for clinical improvement score of 5 or more) Patients with a fever( temperature ≥ 37.5 degrees centigrade) and a positive rapid diagnostic test (RDT) result for malaria Patients with corrected QT interval (QTc) prolongation of > 450ms for males and >470ms for females Pregnant or breastfeeding women Patients on chronic hydroxychloroquine use